Guggenheim initiated coverage of Boundless Bio with a Buy rating and $24 price target. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot Stocks on TipRanks >> Read More on BOLD: Boundless Bio doses first patient in BBI-825 trial Boundless Bio presents preclinical data on BBI-355 Disclaimer & DisclosureReport an Issue
